Treatment adherence and long-term outcomes

CNS Spectrums

Volumn 12, Issue 10 SUPPL. 17, 2007, Pages 21-26

  Kane, John M ^a,b,c  

^a North Shore Long Island Jewish Health System ^*  (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c and Neuroscience ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; FLUPHENAZINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; RISPERIDONE;

AKATHISIA; AKINESIA; ANTICHOLINERGIC SYNDROME; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; METABOLIC DISORDER; MUSCLE RIGIDITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOEDUCATION; RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL SUPPORT; STIGMA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 36049012418     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900026304     Document Type: Review

References (25)

1. Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull. 2005;31(3):705-722.
2. Robinson D, Woerner M, Alvir J, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247.
3. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57(2-3):209-219.
4. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286-290.
5. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
6. Weiden PJ, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract. 2001;7(1):41-47.
7. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891.
8. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630-639.
9. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medicine adherence: Is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159(1):103-108.
10. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209-1222.
11. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
12. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5-19.
13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
14. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196-201.
15. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schiz Bull. 1995;21(3):419-429.
16. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184:509-516.
17. Hudson TJ, Owen RR, Thrush CR, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2):211-216.
18. Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312(7027):345-349.
19. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry. 1998;172:413-419.
20. O'Donnell C, Donohoe G, Sharkey L, et al. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ. 2003;327(7419):834.
21. Byerly MJ, Fisher R, Carmody T, Rush AJ. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66(8):997-1001.
22. Davis J, Barter J, Kane JM. Antipsychotic drugs. In: Kaplan HI and Sadock BJ, eds. Comprehensive Textbook of Psychiatry. 5th ed. Baltimore, Md: Williams & Wilkins; 1989:1591-1626.
23. Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs. 2004;18(2):113-132.
24. Siegel SJ, Winey KI, Gur RE, et al. Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology. 2002;26(6):817-823.
25. Irani F, Dankert M, Brensinger C, et al. Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine. Neuropsychopharmacology. 2004;29(5):960-968.